| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/21/2002 | WO2001003774A3 Pharmaceutical composition for the treatment of calcification |
| 03/21/2002 | WO2000078772A3 Antibiotic agents |
| 03/21/2002 | WO2000076490A3 Methods and compositions for treating urinary frequency and urgency using optically pure (s)-oxybutynin |
| 03/21/2002 | WO2000072835A3 Topical application of muscarinic and opioid agents for treatment of tinnitus |
| 03/21/2002 | WO2000041484A8 Novel use of phospholipids of vegetable and animal origin in nutritional therapy |
| 03/21/2002 | US20020035459 Pharmacokinetic-based drug design tool and method |
| 03/21/2002 | US20020035386 Therapeutic light source and method |
| 03/21/2002 | US20020035277 Using Grignard reagent; antidepressant |
| 03/21/2002 | US20020035267 Tetrazolyl-phenyl acetamide glucokinase activators |
| 03/21/2002 | US20020035266 Tetrazolyl-phenyl acetamide glucokinase activators |
| 03/21/2002 | US20020035264 Therapy for vision disorders |
| 03/21/2002 | US20020035262 7-hetero-bicyclo[2.2.1]-heptanes |
| 03/21/2002 | US20020035260 4-aza-steroids |
| 03/21/2002 | US20020035258 Quinolone carboxylic acid derivatives |
| 03/21/2002 | US20020035246 SMAD-interacting polypeptides and their use |
| 03/21/2002 | US20020035161 O/W emulsions comprising micronized biologically active agents |
| 03/21/2002 | US20020035160 Topical applying; stability |
| 03/21/2002 | US20020035158 Central nervous system disorders; antidepressants |
| 03/21/2002 | US20020035157 Mixture containing vasodilator |
| 03/21/2002 | US20020035156 Administering cyclooxygenase inhibitor |
| 03/21/2002 | US20020035155 Use of creatine analogues and creatine kinase modulators for the prevention and treatment of obesity and its related disorders |
| 03/21/2002 | US20020035153 Kits; containing a compound containing an oxamic acid group |
| 03/21/2002 | US20020035152 Use of inhaled retinoids in the treatment of lung diseases |
| 03/21/2002 | US20020035151 Calcium formate for use as a dietary supplement |
| 03/21/2002 | US20020035150 Adminstering a cannabinoid compound |
| 03/21/2002 | US20020035149 Administering 15-ketolatanoprost |
| 03/21/2002 | US20020035148 Treatment of ocular hypertension |
| 03/21/2002 | US20020035147 Nervous system, psychological disorders |
| 03/21/2002 | US20020035145 Administering mixture of alanine, serine, methylglycine and cycloserine |
| 03/21/2002 | US20020035144 Solubility, bioavailability; antiinflammatory agents |
| 03/21/2002 | US20020035143 Application of 2,3,7,8-tetrachlorodibenzo-para-dioxin (TCDD) as a promoter blocker of cancer |
| 03/21/2002 | US20020035141 Use of melatonin for induction of general anesthesia |
| 03/21/2002 | US20020035140 1-(pyrrlolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| 03/21/2002 | US20020035139 COX-2 inhibitors and the prevention of the side effects of radiation therapy |
| 03/21/2002 | US20020035138 Activating Cl- secretion |
| 03/21/2002 | US20020035135 Oral administering; storage stability |
| 03/21/2002 | US20020035134 Indoline derivatives useful as 5-HT-2C receptor antagonists |
| 03/21/2002 | US20020035133 Medicament containing betasitosterol and/or phytosterol/betasitosterol mixtures |
| 03/21/2002 | US20020035131 Administering paroxetine |
| 03/21/2002 | US20020035130 Antidepressants, therapy for Parkinson's disease |
| 03/21/2002 | US20020035129 Cholinesterase inhibitor |
| 03/21/2002 | US20020035128 Cholinesterase inhibitors |
| 03/21/2002 | US20020035127 Phenylalanine derivatives |
| 03/21/2002 | US20020035126 Side effect reduction |
| 03/21/2002 | US20020035125 Therapeutic combination |
| 03/21/2002 | US20020035123 For treating pain or memory deficiencies related to Alzheimer's disease and other neurodegenerative disorders associated with aging |
| 03/21/2002 | US20020035122 8-azabicyclo[3.2.1]oct-2-ene and -octane derivatives |
| 03/21/2002 | US20020035119 Bioavailable dosage form of loratadine |
| 03/21/2002 | US20020035118 Low molecular weight cell, bone marrow and immune stimulants |
| 03/21/2002 | US20020035117 Theophylline and 3-isobutyl-1-methylxanthine based N-7 substituted derivatives displaying inhibitory activities on type five phosphodiesterase |
| 03/21/2002 | US20020035114 Substituted dimeric compounds |
| 03/21/2002 | US20020035113 Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use |
| 03/21/2002 | US20020035111 Regulating apoptosis using compounds such as (6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2-methyl-pyrazino (2',1':6,1)pyrido(3,4-b)indole-1,4-dione; not having severe side reactions of conventional chemotherapeutics |
| 03/21/2002 | US20020035110 Treatment or prevention of disorders of the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, and sleep apnea |
| 03/21/2002 | US20020035108 Method for treating allergies |
| 03/21/2002 | US20020035107 Highly concentrated stable meloxicam solutions |
| 03/21/2002 | US20020035106 Use of potassium channel agonists for reducing fat food consumption |
| 03/21/2002 | US20020035105 Composition and method combining an antidepressant with an NMDA receptor antagonist, for treating neuropathic pain |
| 03/21/2002 | US20020035104 Integrin receptor inhibitors |
| 03/21/2002 | US20020035102 Azetidine derivatives, their preparation and medicaments containing them |
| 03/21/2002 | US20020035101 Administering antineoplastic amount of dihydroequilin or metabolic conjugate orally, parenterally, transdermally, topically, rectally, intravaginally, intranasally, or intrabronchially |
| 03/21/2002 | US20020035100 Alkyl ether modified polycyclic compounds having a terminal phenol and uses for protection of cells |
| 03/21/2002 | US20020035099 That are antagonists of the progesterone receptor, in a female contraceptive kit |
| 03/21/2002 | US20020035098 Agents and methods for the prevention of initial onset and recurrence of existing cancers |
| 03/21/2002 | US20020035097 Method of preventing and treating chemotherapy-induced alopecia |
| 03/21/2002 | US20020035096 Formulations for treating or preventing mucositis |
| 03/21/2002 | US20020035094 Substituted pyridine compounds and methods of use |
| 03/21/2002 | US20020035093 Methods for the administration of amifostine and related compounds |
| 03/21/2002 | US20020035092 Propanoic acid derivatives |
| 03/21/2002 | US20020035091 Administering thalidomide and irinotecan; avoiding adverse side effects associated with irinotecan |
| 03/21/2002 | US20020035090 Compositions and methods for the treatment of cancer |
| 03/21/2002 | US20020035089 Orlistat compositions |
| 03/21/2002 | US20020035088 Formulated at a certain pH in order to minimize or eliminate compatibility problems between tobramycin and xanthan gum; eye, nose, ear topical solutions |
| 03/21/2002 | US20020035086 Acylated uridine and cytidine and uses thereof |
| 03/21/2002 | US20020035085 Administering a 2'-deoxy-beta-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof |
| 03/21/2002 | US20020035083 CRF2 ligands in combination therapy |
| 03/21/2002 | US20020035077 Pyrrolo[2,3-d]pyrimidine nucleoside analogs |
| 03/21/2002 | US20020035076 Method of treating dermatoses using avermectin compound |
| 03/21/2002 | US20020035074 Administering isoflavone formononetin, or isoflavone daidzein |
| 03/21/2002 | US20020035072 Method for enhancing mutant enzyme activities in lysosomal storage disorders |
| 03/21/2002 | US20020035071 Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites |
| 03/21/2002 | US20020035070 Administering metal complex of an oxidized carbohydrate, wherein oxidized carbohydrate is neither zinc gluconate nor manganese gluconate |
| 03/21/2002 | US20020035069 For use in human performing weight-training exercise |
| 03/21/2002 | US20020035068 Administering 2,3:4,5-bis-O-(1-methylethylidene)-B-D-fructopyranose sulfamate or derivative |
| 03/21/2002 | US20020035067 In ilio-hypogastric-pudendal arterial bed and genitalia by administering to humans therapeutically effective amount of anti-pressor agent |
| 03/21/2002 | US20020035065 Selective MMP inhibitors having reduced side-effects |
| 03/21/2002 | US20020035064 Method for treating atherosclerosis employing an aP2 inhibitor and combination |
| 03/21/2002 | US20020035060 Pharmaceutical compositions, methods, and kits for treatment and diagnosis of lung cancer |
| 03/21/2002 | US20020035059 For achieving circadian rhythm phase-shifting effect in mammal |
| 03/21/2002 | US20020035057 Treatment of movement disorders by administration of 5-hydroxytryptamine receptor/alpha2 adrenergic receptor antagonist compositions |
| 03/21/2002 | US20020035046 Suitable for use in skin care applications, which effectively deliver and/or deposit various benefit agents into and onto the skin and which are relatively non-irritating |
| 03/21/2002 | US20020034821 Methods and compositions for enhancing the delivery of a nucleic acid to a cell |
| 03/21/2002 | US20020034787 Nucleotide sequences coding polypeptides for use in treatment of wounds, burns, ulcers, nervous system disorders and tumors |
| 03/21/2002 | US20020034786 Nucleotide sequences coding G protein coupled receptor; for use in the diagnosis and treatment of defects in signal transduction |
| 03/21/2002 | US20020034774 Treatment or prophylaxis of diseases caused by pilus-forming bacteria |
| 03/21/2002 | US20020034772 Methods and compositions that affect melanogenesis |
| 03/21/2002 | US20020034770 Modulators of cyclin dependent kinases; for use in the treatment of cancer; antitumor agents |
| 03/21/2002 | US20020034764 Diarylsulfonylurea binding proteins |
| 03/21/2002 | US20020034758 Novel human genes and gene expressions products: II |
| 03/21/2002 | US20020034736 Nucleotide sequences coding modulators for use in therapy against tumors, retinopathy, perfusion injuries, fibrosis, artherosclerosis, angiogenesis, inflammation, and restenosis; antiischemic and antitumor agents |